Key features and details
- Mouse monoclonal [GA2B] to Matrix protein 1
- Suitable for: IHC-P, WB, ICC/IF
- Reacts with: Species independent
- Isotype: IgG1
Product nameAnti-Matrix protein 1 antibody [GA2B]
See all Matrix protein 1 primary antibodies
DescriptionMouse monoclonal [GA2B] to Matrix protein 1
Tested applicationsSuitable for: IHC-P, WB, ICC/IFmore details
Species reactivityReacts with: Species independent
Tissue/ cell preparation- Influenza A/ Puerto Rico/ 8/ 34 (H1N1) and A/Bangkok/ 1/ 79 (H3N2) viruses
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.50
Preservative: 0.09% Sodium azide
Concentration information loading...
Purification notes>90% IgG content as established by SDS PAGE
Our Abpromise guarantee covers the use of ab22396 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use at an assay dependent concentration.|
|WB||Use at an assay dependent concentration.|
RelevanceInfluenza virus type A matrix protein, also known as M1, is composed of a 252 amino acid sequence and is type-specific in influenza viruses. It is located inside the viral lipid envelope and plays a key role in virus assembly and replication. M1 can be isolated from particles by removing the envelope with detergents and reducing the pH to 4.0. Influenza viruses are a common and widely spread infectious agent. Like many other viruses, influenza virus are constantly undergoing mutations and thereby avoiding the immune system. The Influenza A Virus M proteins form a continuous shell on the inner side of the lipid bilayer, maintaining the structural integrity of the virus particle through hydrophobic interactions.
- M1 antibody
- Matrix Protein 1 antibody
- Matrix Protein I antibody
- Membrane matrix protein M1 antibody
Immunofluorescence analysis of HeLa cells staining Influenza A Virus M1 using ab22396.
Cells were treated with either 20 µg/ml Prostaglandin A (PGA) or EtOH vehicle control, 3 hours post infection by Influenza A Virus, then fractionated at 9 hours post infection before analysis by immunofluorescence.
ab22396 has been referenced in 16 publications.
- Amarelle L et al. Cardiac glycosides decrease influenza virus replication by inhibiting cell protein translational machinery. Am J Physiol Lung Cell Mol Physiol 316:L1094-L1106 (2019). PubMed: 30892074
- Xie X et al. Influenza Vaccine With Consensus Internal Antigens as Immunogens Provides Cross-Group Protection Against Influenza A Viruses. Front Microbiol 10:1630 (2019). PubMed: 31379782
- Kang HJ et al. Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs. PLoS One 14:e0216871 (2019). PubMed: 31246961
- Desforges JP et al. Environmental contaminant mixtures modulate in vitro influenza infection. Sci Total Environ 634:20-28 (2018). Flow Cyt . PubMed: 29626767
- Nogales A et al. Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines. J Virol 90:6291-302 (2016). WB . PubMed: 27122587